Preferences help
enabled [disable] Abstract
Number of results
2011 | 58 | 3 | 313-319
Article title

Fenoterol did not enhance glucocorticoid-induced skeletal changes in male rats

Title variants
Languages of publication
Glucocorticoids and β2-adrenergic receptor agonists are the most commonly used drugs in the treatment of asthma. Both therapies are potentially dangerous to the skeletal system. The aim of the present study was to investigate the effects of fenoterol, a β2-receptor agonist, on the development of bone changes induced by glucocorticoid (prednisolone) administration in mature male rats. The experiments were carried out on 24-week-old male Wistar rats. The effects of prednisolone 21-hemisuccinate sodium salt (7 mg/kg s.c. daily) or/and fenoterol hydrobromide (1.4 mg/kg i.p. daily), administered for 4 weeks, on the skeletal system were studied. Bone turnover markers, geometric parameters, mass, mass of bone mineral in the tibia, femur and L-4 vertebra, bone histomorphometric parameters and mechanical properties of tibial metaphysis, femoral diaphysis and femoral neck were determined. Both prednisolone and fenoterol had damaging effects on the skeletal system of mature male rats. However, concurrent administration of fenoterol and prednisolone did not result in the intensification of the deleterious skeletal effect of either drug administered separately.
Physical description
  • Department of Pharmacology, Medical University of Silesia, Katowice, Sosnowiec, Poland
  • Department of Pharmacology, Medical University of Silesia, Katowice, Sosnowiec, Poland
  • Department of Pharmacology, Medical University of Silesia, Katowice, Sosnowiec, Poland
  • Department of Pharmacology, Medical University of Silesia, Katowice, Sosnowiec, Poland
  • Department of Pharmacology, Medical University of Silesia, Katowice, Sosnowiec, Poland
  • Department of Pharmacology, Medical University of Silesia, Katowice, Sosnowiec, Poland
  • Beitzel F, Gregorevic P, Ryall JG, Plant DR, Sillence MN, Lynch GS (2004) β2-Adrenoceptor agonist fenoterol enhances functional repair of regenerating rat skeletal muscle after injury. J Appl Physiol 96: 1385-1392.
  • Beitzel F, Sillence MN, Lynch GS (2007) β-Adrenoceptor signaling in regenerating skeletal muscle after β-agonist administration. Am J Physiol Endocrinol Metab 293: E932-E940.
  • Bonnet N, Benhamou CL, Beaupied H, Laroche N, Vico L, Dolleans E, Courteix D (2007a) Doping dose of salbutamol and exercise: deleterious effect on cancellous and cortical bones in adult rats. J Appl Physiol 102: 1502-1509.
  • Bonnet N, Benhamou CL, Brunet-Imbault B, Arlettaz A, Horcajada MN, Richard O, Vico L, Collomp K, Courteix D (2005) Severe bone alteration under β2 agonist treatments: bone mass, microarchitecture and strength analyses in female rats. Bone 37: 622-633.
  • Bonnet N, Laroche N, Beaupied H, Vico L, Dolleans E, Benhamou CL, Courteix D (2007b) Doping dose of salbutamol and exercise training: impact on the skeleton of ovariectomized rats. J Appl Physiol 103: 524-533.
  • Canalis E, Mazziotti G, Giustina A, Bilezikian JP (2007) Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int 18: 1319-1328.
  • Cavalié H, Lac G, Lebecque P, Chanteranne B, Davicco MJ, Barlet JP (2002) Influence of clenbuterol on bone metabolism in exercised or sedentary rats. J Appl Physiol 93: 2034-2037.
  • Chung KF, Caramori G, Adcock IM (2009) Inhaled corticosteroids as combination therapy with β-adrenergic agonists in airways disease: present and future. Eur J Clin Pharmacol 65: 853-871.
  • Dalle Carbonare L, Bertoldo F, Valenti MT, Zenari S, Zanatta M, Sella S, Giannini S, Lo Cascio V (2005) Histomorphometric analysis of glucocorticoid-induced osteoporosis. Micron 36: 645-652.
  • de Nijs RNJ (2008) Glucocorticoid-induced osteoporosis: a review on pathophysiology and treatment options. Minerva Med 99: 23-42.
  • de Vries F, Pouwels S, Lammers JW, Leufkens HG, Bracke M, Cooper C, van Staa TP (2007a) Use of inhaled and oral glucocorticoids, severity of inflammatory disease and risk of hip/femur fracture: a population-based case-control study. J Intern Med 261: 170-177.
  • de Vries F, Pouwels S, Bracke M, Leufkens HG, Cooper C, Lammers JW, van Staa TP (2007b) Use of β2-agonists and risk of hip/femur fracture: a population-based case-control study. Pharmacoepidemiol Drug Saf 16: 612-619.
  • Elefteriou F (2008) Regulation of bone remodeling by the central and peripheral nervous system. Arch Biochem Biophys 473: 231-236.
  • Eickelberg O, Roth M, Lörx R, Bruce V, Rüdiger J, Johnson M, Block LH (1999) Ligand-independent activation of the glucocorticoid receptor by β2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 274: 1005-1010.
  • Folwarczna J, Janiec W, Firlus K, Kaczmarczyk-Sedlak I (1999) Effects of doxycycline on the development of bone damage caused by prednisolone in rats. Pol J Pharmacol 51: 243-251.
  • Folwarczna J, Janiec W, Gawor M, Pytlik M, Kaczmarczyk-Sedlak I, Nowińska B (2004a) Effects of enoxaparin on histomorphometric parameters of bones in rats. Pol J Pharmacol 56: 451-457.
  • Folwarczna J, Janiec W, Śliwiński L (2004b) Effects of heparin and low-molecular-weight heparins on bone mechanical properties in rats. Thromb Haemost 92: 940-946.
  • Folwarczna J, Śliwiński L, Kulig M, Nowińska B, Cegieła U, Pytlik M, Kaczmarczyk-Sedlak I, Trzeciak HI (2007) Effect of propranolol on the glucocorticoid-induced bone changes in young rats. Calcif Tissue Int 80 (Suppl. 1): S126-S127 (abstract).
  • Frost HM (2004) A 2003 update of bone physiology and Wolff's law for clinicians. Angle Orthod 74: 3-15.
  • Graham S, Hammond-Jones D, Gamie Z, Polyzois I, Tsiridis E, Tsiridis E (2008) The effect of β-blockers on bone metabolism as potential drugs under investigation for osteoporosis and fracture healing. Expert Opin Investig Drugs 17: 1281-1299.
  • Hamrick MW, Ferrari SL (2008) Leptin and the sympathetic connection of fat to bone. Osteoporos Int 19: 905-912.
  • Kondo H, Togari A (2011) Continuous treatment with a low-dose β-agonist reduces bone mass by increasing bone resorption without suppressing bone formation. Calcif Tissue Int 88: 23-32.
  • Lelovas PP, Xanthos TT, Thoma SE, Lyritis GP, Dontas IA (2008) The laboratory rat as an animal model for osteoporosis research. Comp Med 58: 424-430.
  • Lovén J, Svitacheva N, Jerre A, Miller-Larsson A, Korn SH (2007) Anti-inflammatory activity of β2-agonists in primary lung epithelial cells is independent of glucocorticoid receptor. Eur Respir J 30: 848-856.
  • Mazziotti G, Angeli A, Bilezikian JP, Canalis E, Giustina A (2006) Glucocorticod-induced osteoporosis: an udpade. Trends Endocrinol Metab 17: 144-149.
  • Milch RA, Rall DP, Tobie JE (1958) Fluorescence of tetracycline antibiotics in bone. J Bone Joint Surg Am 40-A: 897-910.
  • Navarro RP, Schaecher KL, Rice GK (2007) Asthma management guidelines: updates, advances, and new options. J Manag Care Pharm 13 (6 Suppl D): S3-S11.
  • Ogoshi T, Hagino H, Fukata S, Tanishima S, Okano T, Teshima R (2008) Influence of glucocorticoid on bone in 3-, 6-, and 12-month-old rats as determined by bone mass and histomorphometry. Mod Rheumatol 18: 552-561.
  • Pasaoglu G, Gok H, Mungan D, Sonel B, Yalcin P, Misirligil Z (2006) Does the combination of inhaled steroids with long acting β2 agonists decrease the risk for osteoporosis? A 1-year prospective follow-up study. Rheumatol Int 27: 141-146.
  • Pytlik M, Folwarczna J, Janiec W (2004) Effects of doxycycline on mechanical properties of bones in rats with ovariectomy-induced osteopenia. Calcif Tissue Int 75: 225-230.
  • Radzki RP, Bieńko M, Kapica M, Puzio I, Dobrowolski P, Filip R (2006) Effect of β2-adrenergic receptor agonist clenbuterol on the mineralization of tibiae in rats with established osteopenia. Medycyna Wet 62: 824-826 (in Polish).
  • Ryall JG, Plant DR, Gregorevic P, Sillence MN, Lynch GS (2004) β2-Agonist administration reverses muscle wasting and improves muscle function in aged rats. J Physiol 555: 175-188.
  • Stuermer EK, Komrakova M, Werner C, Wicke M, Kolios L, Sehmisch S, Tezval M, Utesch C, Mangal O, Zimmer S, Dullin C, Stuermer KM (2010) Musculoskeletal response to whole-body vibration during fracture healing in intact and ovariectomized rats. Calcif Tissue Int 87: 168-180.
  • Stürmer EK, Seidlová-Wuttke D, Sehmisch S, Rack T, Wille J, Frosch KH, Wuttke W, Stürmer KM (2006) Standardized bending and breaking test for the normal and osteoporotic metaphyseal tibias of the rat: effect of estradiol, testosterone, and raloxifene. J Bone Miner Res 21: 89-96.
  • Śliwiński L, Folwarczna J, Nowińska B, Cegieła U, Pytlik M, Kaczmarczyk-Sedlak I, Trzeciak H, Trzeciak HI (2009) A comparative study of the effects of genistein, estradiol and raloxifene on the murine skeletal system. Acta Biochim Pol 56: 261-270.
  • Śliwiński L, Folwarczna J, Nowińska B, Trzeciak HI (2008) Differential effects of fenoterol on the skeletal system of non-ovariectomized and ovariectomized rats. Calcif Tissue Int 82 (Suppl 1): S225 (abstract).
  • Takeda S, Elefteriou F, Levasseur R, Liu X, Zhao L, Parker KL, Armstrong D, Ducy P, Karsenty G (2002) Leptin regulates bone formation via the sympathetic nervous system. Cell 111: 305-317.
  • Takeda S, Karsenty G (2008) Molecular bases of the sympathetic regulation of bone mass. Bone 42: 837-840.
  • Togari A, Arai M (2008) Pharmacological topics of bone metabolism: the physiological function of the sympathetic nervous system in modulating bone resorption. J Pharmacol Sci 106: 542-546.
  • Ton FN, Gunawardene SC, Lee H, Neer RM (2005) Effects of low-dose prednisone on bone metabolism. J Bone Miner Res 20: 464-470.
  • Turner CH, Burr DB (1993) Basic biomechanical measurements of bone: a tutorial. Bone 14: 595-608.
  • Vestergaard P, Rejnmark L, Mosekilde L (2007) Fracture risk in patients with chronic lung diseases treated with bronchodilator drugs and inhaled and oral corticosteroids. Chest 132: 1599-1607.
  • van Brussel MS, Bultink IEM, Lems WF (2009) Prevention of glucocorticoid-induced osteoporosis. Expert Opin Pharmacother 10: 997-1005.
  • Westbroek I, Waarsing JH, van Leeuwen JP, Waldum H, Reseland JE, Weinans H, Syversen U, Gustafsson BI (2007) Long-term fluoxetine administration does not result in major changes in bone architecture and strength in growing rats. J Cell Biochem 101: 360-368.
  • Zeman RJ, Hirschman A, Hirschman ML, Guo G, Etlinger JD (1991) Clenbuterol, a β2-receptor agonist, reduces net bone loss in denervated hindlimbs. Am J Physiol 261: E285-E289.
Document Type
Publication order reference
YADDA identifier
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.